7.26
+1.42
+(24.32%)
At close: April 16 at 4:00:00 PM EDT
7.39
+0.13
+(1.79%)
After hours: April 16 at 7:21:37 PM EDT
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Expense
36,602
36,602
32,486
13,896
21,486
Operating Income
-36,602
-36,602
-32,486
-13,896
-21,486
Net Non Operating Interest Income Expense
1,314
1,314
1,124
162
--
Other Income Expense
-190
-190
-114
-145
-222
Pretax Income
-35,478
-35,478
-31,476
-13,879
-21,708
Net Income Common Stockholders
-35,478
-35,478
-31,476
-13,879
-21,708
Diluted NI Available to Com Stockholders
-35,478
-35,478
-31,476
-13,879
-21,708
Basic EPS
-16.38
-12.17
-24.92
-20.00
-38.75
Diluted EPS
-16.38
-12.17
-24.92
-20.00
-38.75
Basic Average Shares
1,845.88
2,915.89
1,262.84
695.34
558.71
Diluted Average Shares
1,845.88
2,915.89
1,262.84
695.34
558.71
Total Operating Income as Reported
-36,602
-36,602
-32,486
-13,896
-21,486
Total Expenses
36,602
36,602
32,486
13,896
21,486
Net Income from Continuing & Discontinued Operation
-35,478
-35,478
-31,476
-13,879
-21,708
Normalized Income
-35,478
-35,478
-31,476
-13,879
-21,708
Interest Income
1,314
1,314
1,124
162
--
Net Interest Income
1,314
1,314
1,124
162
--
EBIT
-36,602
-36,602
-32,486
-13,896
-21,486
EBITDA
-36,563
-36,563
-32,477
-13,896
-21,450
Reconciled Depreciation
39
39
9
--
36
Net Income from Continuing Operation Net Minority Interest
-35,478
-35,478
-31,476
-13,879
-21,708
Normalized EBITDA
-36,563
-36,563
-32,477
-13,896
-21,450
12/31/2021 - 4/13/2017
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
PVLA Palvella Therapeutics, Inc.
24.40
+1.96%
SLRN Acelyrin, Inc.
2.2000
-1.35%
IMRN Immuron Limited
1.7100
-1.72%
ENGN enGene Holdings Inc.
3.9600
-1.00%
GLUE Monte Rosa Therapeutics, Inc.
4.4100
-0.45%
TECX Tectonic Therapeutic, Inc.
17.56
-2.12%
ACTU Actuate Therapeutics, Inc. Common stock
8.23
+3.52%
MNPR Monopar Therapeutics Inc.
38.02
-0.89%
SYRE Spyre Therapeutics, Inc.
12.42
-2.28%
BOLD Boundless Bio, Inc.
1.3100
-2.96%